Cargando…

Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy

BACKGROUND: Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy. However, predictive factors for early relapse during durvalumab maintenance have not yet been iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Jung Hyun, Yeo, Chang Dong, Park, Chan Kwon, Kim, Sung Kyoung, Kim, Ju Sang, Kim, Yong Hyun, Kim, Jin Woo, Kim, Seung Joon, Lee, Sang Haak, Kang, Hye Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493476/
https://www.ncbi.nlm.nih.gov/pubmed/37519059
http://dx.doi.org/10.1111/1759-7714.15050
_version_ 1785104483338944512
author Nam, Jung Hyun
Yeo, Chang Dong
Park, Chan Kwon
Kim, Sung Kyoung
Kim, Ju Sang
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Haak
Kang, Hye Seon
author_facet Nam, Jung Hyun
Yeo, Chang Dong
Park, Chan Kwon
Kim, Sung Kyoung
Kim, Ju Sang
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Haak
Kang, Hye Seon
author_sort Nam, Jung Hyun
collection PubMed
description BACKGROUND: Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy. However, predictive factors for early relapse during durvalumab maintenance have not yet been identified. METHODS: The present study included the lung cancer cohort of the Catholic Medical Centers at the Catholic University of Korea from January 2018 to December 2021. A total of 51 NSCLC patients treated with durvalumab consolidation therapy after definitive CCRT were included in the analysis. Early relapse was defined as patients experiencing relapse within 6 months of starting initial durvalumab therapy. RESULTS: Among the 51 patients, 15 (29.4%) relapsed during the study period. Median time from initial therapy of durvalumab to progression was 451.00 ± 220.87 days (95% confidence interval [CI]: 18.10–883.90) in overall patients. In multivariate analysis, younger age (adjusted odds ratio [aOR], 0.792; 95% CI: 0.642–0.977; p = 0.030), higher pack‐years (aOR, 1.315; 95% CI: 1.058–1.635; p = 0.014), non‐COPD (aOR, 0.004; 95% CI: 0.000–0.828; p = 0.004) and anemia (aOR, 234.30; 95% CI: 1.212–45280.24; p = 0.042), were independent predictive factors for early relapse during durvalumab consolidation therapy. CONCLUSION: Younger age, higher number of pack‐years, non‐COPD, and anemia were independent predictive factors for early relapse during durvalumab consolidation therapy in patients with unresectable stage III NSCLC after definitive CCRT. Careful patient selection and clinical attention are needed for high‐risk individuals.
format Online
Article
Text
id pubmed-10493476
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-104934762023-09-12 Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy Nam, Jung Hyun Yeo, Chang Dong Park, Chan Kwon Kim, Sung Kyoung Kim, Ju Sang Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Lee, Sang Haak Kang, Hye Seon Thorac Cancer Original Articles BACKGROUND: Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy. However, predictive factors for early relapse during durvalumab maintenance have not yet been identified. METHODS: The present study included the lung cancer cohort of the Catholic Medical Centers at the Catholic University of Korea from January 2018 to December 2021. A total of 51 NSCLC patients treated with durvalumab consolidation therapy after definitive CCRT were included in the analysis. Early relapse was defined as patients experiencing relapse within 6 months of starting initial durvalumab therapy. RESULTS: Among the 51 patients, 15 (29.4%) relapsed during the study period. Median time from initial therapy of durvalumab to progression was 451.00 ± 220.87 days (95% confidence interval [CI]: 18.10–883.90) in overall patients. In multivariate analysis, younger age (adjusted odds ratio [aOR], 0.792; 95% CI: 0.642–0.977; p = 0.030), higher pack‐years (aOR, 1.315; 95% CI: 1.058–1.635; p = 0.014), non‐COPD (aOR, 0.004; 95% CI: 0.000–0.828; p = 0.004) and anemia (aOR, 234.30; 95% CI: 1.212–45280.24; p = 0.042), were independent predictive factors for early relapse during durvalumab consolidation therapy. CONCLUSION: Younger age, higher number of pack‐years, non‐COPD, and anemia were independent predictive factors for early relapse during durvalumab consolidation therapy in patients with unresectable stage III NSCLC after definitive CCRT. Careful patient selection and clinical attention are needed for high‐risk individuals. John Wiley & Sons Australia, Ltd 2023-07-30 /pmc/articles/PMC10493476/ /pubmed/37519059 http://dx.doi.org/10.1111/1759-7714.15050 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nam, Jung Hyun
Yeo, Chang Dong
Park, Chan Kwon
Kim, Sung Kyoung
Kim, Ju Sang
Kim, Yong Hyun
Kim, Jin Woo
Kim, Seung Joon
Lee, Sang Haak
Kang, Hye Seon
Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
title Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
title_full Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
title_fullStr Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
title_full_unstemmed Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
title_short Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
title_sort identification of predictive factors for early relapse in patients with unresectable stage iii non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493476/
https://www.ncbi.nlm.nih.gov/pubmed/37519059
http://dx.doi.org/10.1111/1759-7714.15050
work_keys_str_mv AT namjunghyun identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT yeochangdong identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT parkchankwon identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT kimsungkyoung identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT kimjusang identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT kimyonghyun identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT kimjinwoo identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT kimseungjoon identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT leesanghaak identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy
AT kanghyeseon identificationofpredictivefactorsforearlyrelapseinpatientswithunresectablestageiiinonsmallcelllungcancerreceivingconsolidationdurvalumabafterconcurrentchemoradiationtherapy